Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BC
Briacell Therapeutics Corp. Common Shares
BCTX
Mkt Cap
$29.8M
Volume
131.46K
Next Earnings
October 21st
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BC
BCTX
BC
Briacell Therapeutics Corp. Common Shares
BCTX
News
·
BriaCell Therapeutics Announces Pricing of Offering
Mkt Cap
$29.6M
Volume
131.46K
Next Earnings
October 21st
Chart
Financials
Earnings
News
About
Insider
Filings
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Therapeutics Corp. announced a best-efforts offering of 1,449,300 common shares at $3.25 per share, expected to raise approximately $4.7 million in gross proceeds. The offering is scheduled to close on June 2, 2026, with net proceeds designated for working capital, general corporate purposes, and advancement of business objectives. ThinkEquity is serving as the sole placement agent.
GlobeNewswire Inc. · May 31, 2026
BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics plans to consolidate its common shares at a 10:1 ratio to maintain Nasdaq listing requirements, effective August 25, 2025.
GlobeNewswire Inc. · Aug 6, 2025
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
BriaCell reported promising Phase 2 survival data for Bria-IMT immunotherapy in metastatic breast cancer, showing improved median overall survival compared to Trodelvy and single-agent chemotherapy across triple-negative and hormone receptor-positive breast cancer subtypes.
GlobeNewswire Inc. · Jul 11, 2025
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.
Benzinga · May 1, 2025
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
BriaCell Therapeutics Corp. announced the pricing of a $13.8 million public offering, with each unit consisting of one common share (or pre-funded warrant) and one warrant. The company plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.
GlobeNewswire Inc. · Apr 25, 2025
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
BriaCell Therapeutics, a clinical-stage biotechnology company, will present three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The posters will cover topics related to their cancer immunotherapy pipeline, including Bria-ABC1, Bria-IMT, and Bria-OTS+.
GlobeNewswire Inc. · Mar 26, 2025
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
The Data Safety Monitoring Board (DSMB) has recommended the continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer, as no safety concerns were identified. This is a positive development for the company's groundbreaking immunotherapy treatment.
GlobeNewswire Inc. · Mar 20, 2025
BriaCell Therapeutics Announces Closing of Public Offering
BriaCell Therapeutics announced the closing of its public offering, raising $3.05 million. The company plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.
Benzinga · Feb 5, 2025
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares
BriaCell Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of common shares. The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives.
Benzinga · Feb 3, 2025
BriaCell Announces Completion of 15:1 Share Consolidation
BriaCell Therapeutics Corp. has completed a 15-to-1 share consolidation to comply with Nasdaq listing requirements. The post-consolidation shares will begin trading on January 29, 2025, under the same tickers on the TSX and Nasdaq.
GlobeNewswire Inc. · Jan 27, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
BC
BCTX
Briacell Therapeutics Corp. Common Shares
Buy
Sell
Market
Limit
Soon
BCTX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any BCTX yet.
Related Tickers
Earnings